Although preclinical studies have demonstrated promising outcomes, more randomized controlled trials are needed to assess whether GLP-1 can consistently improve cognitive function in patients with diabetes or those at risk of neurodegenerative conditions. The gene discussed is GCG; the disease is diabetes mellitus.